Transforming CML patient monitoring with ICON’s innovative RNA-based NGS assay

-



Managing chronic myeloid leukemia (CML) can be challenging, especially when it comes to accurately tracking how well patients respond to treatment and spotting any resistance. Traditional testing methods often miss uncommon gene variations and small mutations.

ICON Specialty Laboratory Solutions has created a new, advanced test using next-generation sequencing (NGS) technology. Based on RNA technology, ICON’s new assay offers huge improvements on how CML is monitored.
Understanding the challenges in CML molecular monitoring

Approximately 98% of CML patients exhibit the common e14a2 or e13a2 BCR::ABL1 transcript types, while the remaining have atypical transcripts like e1a2 or e19a2. Despite the effectiveness of tyrosine kinase inhibitors (TKIs) in treating CML, resistance often develops due to mutations in the tyrosine kinase domain (TKD) or the myristoyl binding site of BCR-ABL1. This necessitates precise identification and monitoring of BCR::ABL1 transcripts and potential resistance mutations.


Current standard practice involves using multiplex PCR/Sanger or fusion detection NGS assays to identify the BCR::ABL1 transcript type at diagnosis. Subsequently, transcript-specific qPCR (such as e13/14a2 RT-qPCR) and sequencing assays (Sanger or NGS) are employed to monitor transcript levels and detect TKI resistance mutations. However, these methods have limitations, including the potential to overlook atypical transcripts and generate low-level false positives, complicating high-specificity mutation detection.
A novel RNA-based NGS assay

To address these challenges, ICON Specialty Laboratories has developed and validated a custom RNA-based NGS assay known as Dup-Seq BCR::ABL1. This innovative assay enables the identification of both common and atypical BCR::ABL1 transcript types and detects resistance mutations with superior sensitivity and accuracy, even at a variant allele frequency (VAF) as low as 1%.
Advantages of the Dup-Seq BCR::ABL1 assay

The Dup-Seq BCR::ABL1 assay offers several significant benefits over traditional methods.

One is comprehensive transcript identification. ICON’s assay can identify both common and atypical BCR::ABL1 transcripts, ensuring no transcript type is overlooked.

Another is high sensitivity and specificity. The assay’s enhanced sensitivity allows for the detection of mutations at VAFs as low as 1%, compared to the 3% threshold required by standard NGS assays. This early detection capability can be crucial for timely therapeutic intervention.


Finally, streamlined workflow. By combining transcript typing and mutation detection into a single assay, Dup-Seq simplifies the molecular testing workflow, making it more efficient and less error-prone.
Impact on clinical and trial settings

In routine clinical diagnostics, the Dup-Seq BCR::ABL1 assay can guide the selection of appropriate RT-qPCR assays for monitoring transcript level changes in new CML patients. In clinical trials, the assay’s ability to provide baseline transcript type identification and mutation testing is invaluable. During treatment, Dup-Seq can monitor the emergence and evolution of resistance mutations, offering a comprehensive view of the patient’s molecular response to therapy.

The assay’s capability to detect changes in transcript type during treatment also serves as a quality control measure, ensuring sample integrity and prompt repeat testing if discrepancies arise.

ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients. By addressing the limitations of traditional methods, this assay enhances the accuracy and efficiency of molecular monitoring, offering clinicians and researchers a powerful tool in the fight against CML.


Event : International Top Pharmaceutical Awards 

Visit: toppharmaceutical.org  

 Registration: https://toppharmaceutical.org/award-registration/ Award Nomination : toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee Member Nomination : toppharmaceutical.org/member-submission/?ecategory=Membership&rcategory=Member

For Enquiries : pharmaquerys123@gmail.com

Get Connected Here  

 ---------------------------------  

 ---------------------------------  

 Pinterest: pinterest.com/pharmaemail/  

 Twitter: x.com/TopPharmaaward 

 Instagram: instagram.com/toppharma23/  Y

youtube: youtube.com/channel/UC2MR7HcTZsuBpTgmJzugU_g  

 Blogger:blogger.com/u/1/blog/stats/week/120290426853650288  

 Tumbler : tumblr.com/blog/top-pharmaceutical-awards-23


Comments

Post a Comment

Popular posts from this blog

Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial

-
Image
Sanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiple myeloma patients remain stable without disease progression. This was demonstrated in a Phase III trial (NCT03617731) with 662 newly diagnosed patients who were eligible for a stem cell transplant. The trial found that adding Sarclisa to the standard drugs – lenalidomide, bortezomib, and dexamethasone (Rvd) – resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy. Sanofi said that these results reinforce the potential of Sarclisa as a backbone therapy when added to the current standard of care in various multiple myeloma patient populations. These recent findings build on data from 2021, where the trial met a different primary endpoint of minimal residual disease (MRD) negativity after induction therapy and before transplant. Around 50.1% of the newly diagnosed multiple myeloma patients achiev...
Read more

MDMA Papers Retracted for ‘Unethical Conduct’ on Heels of Lykos’ FDA Rejection

-
Image
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication. The medical journal Psychopharmacology on Saturday retracted three papers related to the use of the psychiatric substance MDMA for the treatment of post-traumatic stress disorder. The decision to pull the studies was driven by “protocol violations amounting to unethical conduct” at one of the study sites, according to the journal’s retraction note. The authors of the studies also confirmed to Psychopharmacology that they knew of these breaches when they submitted their manuscript “but did not disclose this information to the journal or remove data generated by this site from their analysis.” Many of the authors failed to fully disclose a “potential competing interest, ” according to the retraction notice, while some of the researchers were affiliated with either the Multidisciplinary Association for Psychedelic...
Read more

Cell and gene therapy companies must demonstrate strong value proposition for investment

-
Image
Investment for companies developing cell and gene therapies (CGTs) was discussed during the GenScript Biotech Global Forum London 2024 conference held on 20 November 2024. Following a sharp drop in CGT investment in 2022, trends suggest that CGT investment is currently undergoing a “renormalisation”. However, investors continue to be selective, said speakers Josh Resnik, senior managing director at RA Capital Management, and Ping Shek, managing director at Stifel’s Healthcare Investment Banking Division. CGTs have faced challenges attracting investment due to the large amount of capital required to manufacture CGTs, as well as hurdles relating to reimbursement of one-off, high-cost therapies and patient access. Resnik noted that investor sentiment about CGTs was impacted by competitive pressures from “not-so-complicated biologics” such as antibody-drug conjugates, radiopharmaceuticals, and T-cell engagers in oncology and immunology. Resnik noted that CGTs must demonstrate a stron...
Read more